|
1
|
Ridge CA and Boiselle PM: Optimizing the
lung cancer screening interval: The world is waiting. J Thorac Dis.
8:E1369–E1370. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xing P, Wang S, Hao X, Zhang T and Li J:
Clinical data from the real world: Efficacy of Crizotinib in
Chinese patients with advanced ALK-rearranged non-small cell lung
cancer and brain metastases. Oncotarget. 7:84666–84674. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gao L, Xie S, Liu H, Liu P, Xiong Y, Da J,
Que C, Dai H and Wang C: Lung cancer in patients with combined
pulmonary fibrosis and emphysema revisited with the 2015 World
Health Organization classification of lung tumors. Clin Respir J.
12:652–658. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhukovsky M, Varaksin A and Pakholkina O:
Statistical analysis of observational study of the influence of
radon and other risk factors on lung cancer incidence. Radiat Prot
Dosimetry. 160:108–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global Cancer Statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu B, Yuan M, Sun Y, Cheng Z, Zhang Z,
Hou S, Wang X and Liu J: Incidence and risk of hepatic toxicities
associated with anaplastic lymphoma kinase inhibitors in the
treatment of non-small-cell lung cancer: A systematic review and
meta-analysis. Oncotarget. 9:9480–9488. 2017.PubMed/NCBI
|
|
8
|
Leitinger M, Varosanec MV, Pikija S, Wass
RE, Bandke D, Weis S, Studnicka M, Grinzinger S, McCoy MR, Hauer L
and Sellner J: Fatal necrotizing encephalopathy after treatment
with nivolumab for squamous non-small cell lung cancer: Case report
and review of the literature. Front Immunol. 9:1082018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang JC, Mok T, Han B, Orlando M, Puri T
and Park K: A review of regimens combining pemetrexed with an
epidermal growth factor receptor tyrosine kinase inhibitor in the
treatment of advanced nonsquamous non-small-cell lung cancer. Clin
Lung Cancer. 19:27–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takamori S, Toyokawa G, Takada K, Shoji F,
Okamoto T and Maehara Y: Combination therapy of radiotherapy and
Anti-PD-1/PD-L1 treatment in non-small-cell lung cancer: A
Mini-review. Clin Lung Cancer. 19:12–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bamji-Stocke S, van Berkel V, Miller DM
and Frieboes HB: A review of metabolism-associated biomarkers in
lung cancer diagnosis and treatment. Metabolomics. 14:812018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vergnenègre A and Chouaïd C: Review of
economic analyses of treatment for non-small-cell lung cancer
(NSCLC). Expert Rev Pharmacoecon Outcomes Res. 18:519–528. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang X, Li M, Yang X, Zhao M, Huang Y, Dai
X, Jiang T, Feng M, Zhan C and Wang Q: Uniport versus multiport
video-assisted thoracoscopic surgery in the perioperative treatment
of patients with T1-3N0M0 non-small cell lung cancer: A systematic
review and meta-analysis. J Thorac Dis. 10:2186–2195. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki H, Hyodo I and Hasegawa Y:
Prediction of decannulation, oral intake recovery, overall survival
and lung metastasis following oral malignant tumor resection and
reconstruction. Oncol Lett. 15:2686–2694. 2018.PubMed/NCBI
|
|
15
|
Deng Y, Yang Y, Yao B, Ma L, Wu Q, Yang Z,
Zhang L and Liu B: Paracrine signaling by VEGF-C promotes non-small
cell lung cancer cell metastasis via recruitment of
tumor-associated macrophages. Exp Cell Res. 364:208–216. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song W, Kuang J, Li CX, Zhang M, Zheng D,
Zeng X, Liu C and Zhang XZ: Enhanced immunotherapy based on
photodynamic therapy for both primary and lung metastasis tumor
eradication. ACS Nano. 12:1978–1989. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du Q, Yu R, Wang H, Yan D, Yuan Q, Ma Y,
Slamon D, Hou D, Wang H and Wang Q: Significance of
tumor-associated autoantibodies in the early diagnosis of lung
cancer. Clin Respir J. 12:2020–2028. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cormio A, Cormio G, Musicco C, Sardanelli
AM, Gasparre G and Gadaleta MN: Mitochondrial changes in
endometrial carcinoma: Possible role in tumor diagnosis and
prognosis (review). Oncol Rep. 33:1011–1018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cherkashin M, Aniskhin M, Berezina N and
Puchkov D: CT and PET/CT fusion for lung cancer biopsy planning.
BMJ Case Rep. 2017(pii): bcr-2017-221972. 2017.PubMed/NCBI
|
|
20
|
Lim CG, Shin KM, Lim JS, Lim JK, Kim HJ,
Kim WH, Cho SH, Cha SI, Lee EB, Seock Y and Jeong SY: Predictors of
conversion to thoracotomy during video-assisted thoracoscopic
surgery lobectomy in lung cancer: Additional predictive value of
FDG-PET/CT in a tuberculosis endemic region. J Thorac Dis.
9:2427–2436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gensheimer MF, Hong JC, Chang-Halpenny C,
Zhu H, Eclov NCW, To J, Murphy JD, Wakelee HA, Neal JW, Le QT, et
al: Mid-radiotherapy PET/CT for prognostication and detection of
early progression in patients with stage III non-small cell lung
cancer. Radiother Oncol. 125:338–343. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Q, Luo W, Zhao Y, Xu F and Zhou Q: The
utility of 18F-FDG PET/CT for the diagnosis of adrenal metastasis
in lung cancer: A PRISMA-compliant meta-analysis. Nucl Med Commun.
38:1117–1124. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan N, Zhang X, Cao Y, Jiang X, Zhao S,
Feng Y, Fan Y, Lu Z and Gao H: Contrast-enhanced computerized
tomography combined with a targeted nanoparticle contrast agent for
screening for early-phase non-small cell lung cancer. Exp Ther Med.
14:5063–5068. 2017.PubMed/NCBI
|
|
24
|
Li N, Han L and Jing H: Contrast-enhanced
ultrasound with a novel nanoparticle contrast agent for clinical
diagnosis in patients with non-small cell lung cancer. Exp Ther
Med. 14:3768–3773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicholls FJ, Rotz MW, Ghuman H, MacRenaris
KW, Meade TJ and Modo M: DNA-gadolinium-gold nanoparticles for in
vivo T1 MR imaging of transplanted human neural stem cells.
Biomaterials. 77:291–306. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiao L, Tian X, Harihar S, Li Q, Li L,
Welch DR and Zhou A: Gd2O3-doped silica @ Au
nanoparticles for in vitro imaging cancer biomarkers using
surface-enhanced Raman scattering. Spectrochim Acta A Mol Biomol
Spectrosc. 181:218–225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deng H, Chen F, Yang C, Chen M, Li L and
Chen D: Effect of Eu doping concentration on fluorescence and
magnetic resonance imaging properties of
Gd2O3:Eu3+ nanoparticles used as
dual-modal contrast agent. Nanotechnology. 29:4156012018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Wang T, Zheng Y, Yan C, Gu W and
Ye L: Comparative toxicity and contrast enhancing assessments of
Gd2O3@BSA and MnO2@BSA
nanoparticles for MR imaging of brain glioma. Biochem Biophys Res
Commun. 499:488–492. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wirth LJ, Tahara M, Robinson B, Francis S,
Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, et
al: Treatment-emergent hypertension and efficacy in the phase 3
Study of (E7080) lenvatinib in differentiated cancer of the thyroid
(SELECT). Cancer. 124:2365–2372. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shao Y, Tian X, Hu W, Zhang Y, Liu H, He
H, Shen Y, Xie F and Li L: The properties of Gd2O3-assembled silica
nanocomposite targeted nanoprobes and their application in MRI.
Biomaterials. 33:6438–6446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wojcik E and Kulpa JK:
Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell
lung cancer diagnosis, monitoring and evaluation of treatment
response. Lung Cancer (Auckl). 8:231–240. 2017.PubMed/NCBI
|
|
32
|
Reck M and Rabe KF: Precision diagnosis
and treatment for advanced non-small-cell lung cancer. N Engl J
Med. 377:849–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou GH, Yang WH and Sun B: Clinical
impact of serum miR-661 in diagnosis and prognosis of non-small
cell lung cancer. Eur Rev Med Pharmacol Sci. 21:5696–5701.
2017.PubMed/NCBI
|
|
34
|
Labbé C, Anderson M, Simard S, Tremblay L,
Laberge F, Vaillancourt R and Lacasse Y: Wait times for diagnosis
and treatment of lung cancer: A single-centre experience. Curr
Oncol. 24:367–373. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tzouvelekis A, Spagnolo P, Bonella F,
Vancheri C, Tzilas V, Crestani B, Kreuter M and Bouros D: Patients
with IPF and lung cancer: Diagnosis and management. Lancet Respir
Med. 6:86–88. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Jin G and Su D: Comparison of
Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of
brain metastases in lung cancer patients: A meta-analysis of 5
prospective studies. Oncotarget. 8:35743–35749. 2017.PubMed/NCBI
|
|
37
|
Wang H, Machtaler S, Bettinger T, Lutz AM,
Luong R, Bussat P, Gambhir SS, Tranquart F, Tian L and Willmann JK:
Molecular imaging of inflammation in inflammatory bowel disease
with a clinically translatable dual-selectin-targeted US contrast
agent: Comparison with FDG PET/CT in a mouse model. Radiology.
267:818–829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aschoff P, Plathow C, Beyer T, Lichy MP,
Erb G, Öksüz MÖ, Claussen CD and Pfannenberg C: Multiphase
contrast-enhanced CT with highly concentrated contrast agent can be
used for PET attenuation correction in integrated PET/CT imaging.
Eur J Nucl Med Mol Imaging. 39:316–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hyafil F, Cornily JC, Rudd JH, Machac J,
Feldman LJ and Fayad ZA: Quantification of inflammation within
rabbit atherosclerotic plaques using the macrophage-specific CT
contrast agent N1177: A comparison with 18F-FDG PET/CT and
histology. J Nucl Med. 50:959–965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao J, Li L, Liu X, Guo R and Zhao B:
Contrast-enhanced magnetic resonance imaging with a novel nano-size
contrast agent for the clinical diagnosis of patients with lung
cancer. Exp Ther Med. 15:5415–5421. 2018.PubMed/NCBI
|
|
41
|
An YS, Sheen SS, Oh YJ, Hwang SC and Yoon
JK: Nonionic intravenous contrast agent does not cause clinically
significant artifacts to 18F-FDG PET/CT in patients with lung
cancer. Ann Nucl Med. 21:585–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nishio M, Horai T, Horiike A, Nokihara H,
Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio
K, et al: Phase 1 study of lenvatinib combined with carboplatin and
paclitaxel in patients with non-small-cell lung cancer. Br J
Cancer. 109:538–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu Y, Zhang H, Xiang J, Mao Z, Shen G,
Yang F, Liu Y, Wang W, Du N, Zhang J and Tang Y: Ultrasensitive and
high specific detection of non-small-cell lung cancer cells in
human serum and clinical pleural effusion by aptamer-based
fluorescence spectroscopy. Talanta. 179:501–506. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai NL, Lau ATY, Yu FY, Wu DD, Dai LJ, Mo
HY, Lin CM and Xu YM: Purification and characterization of a highly
specific polyclonal antibody against human extracellular
signal-regulated kinase 8 and its detection in lung cancer. PLoS
One. 12:e01847552017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sun Y, Liu S, Qiao Z, Shang Z, Xia Z, Niu
X, Qian L, Zhang Y, Fan L, Cao CX and Xiao H: Systematic comparison
of exosomal proteomes from human saliva and serum for the detection
of lung cancer. Anal Chim Acta. 982:84–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ohliger MA, von Morze C, Marco-Rius I,
Gordon J, Larson PEZ, Bok R, Chen HY, Kurhanewicz J and Vigneron D:
Combining hyperpolarized13 C MRI with a liver-specific
gadolinium contrast agent for selective assessment of hepatocyte
metabolism. Magn Reson Med. 77:2356–2363. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Uran S, Landmark K, Normann PT, Hals PA,
Toft KG and Skotland T: A respiration-metabolism chamber system and
a GC-MS method developed for studying exhalation of perfluorobutane
in rats after intravenous injection of the ultrasound contrast
agent Sonazoid. J Pharm Biomed Anal. 39:746–751. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Skotland T, Sontum PC and Oulie I: In
vitro stability analyses as a model for metabolism of ferromagnetic
particles (Clariscan), a contrast agent for magnetic resonance
imaging. J Pharm Biomed Anal. 28:323–329. 2002. View Article : Google Scholar : PubMed/NCBI
|
